001060 - JW Pharmaceutical

001060 Summary

Biopharma

Stock Price & Overview

₩27,500 +350 (+1.29%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩27,500 ≈ US$20 · Market cap ₩0.6tn (≈ $457m)

001060 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	775.3	719.4	748.5	684.4	606.6	547.3	511.3	537.2	502.9	467.5	434.4
Cost of Revenue	416.0	395.9	413.0	396.4	372.2	369.8	350.2	340.1	314.3	294.1	273.7
Gross Profit	359.3	323.5	335.5	288.0	234.4	177.5	161.1	197.0	188.6	173.3	160.6
Selling, General & Administrative	264.9	241.0	235.2	225.0	203.2	178.8	180.1	175.5	166.9	148.8	139.1
Operating Income	94.5	82.5	100.3	63.0	31.2	-1.3	-19.0	21.6	21.7	24.5	21.5
Finance Income	8.5	10.5	12.7	16.3	5.6	3.8	3.6	8.2	3.0	9.3	5.8
Finance Costs	8.8	14.6	25.0	-25.2	-15.7	-15.9	-20.6	-19.5	-28.2	25.2	25.9
Pretax Income	88.8	82.4	54.8	45.4	20.5	-13.2	-34.3	10.2	-1.3	7.1	2.1
Income Tax Expense	27.3	17.4	16.4	15.5	22.0	2.1	9.1	-2.2	0.6	-18.0	-0.1
Net Income	61.5	65.0	38.4	29.9	-1.4	-15.3	-25.3	8.1	-0.7	-10.9	2.0
Total Comprehensive Income	60.5	74.5	35.5	34.8	0.4	-15.4	-27.6	4.0	-1.5	-14.4	0.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	605.3	604.6	645.0	628.0	633.1	549.1	573.2	593.8	630.9	651.1	613.5
Current Assets	296.5	306.4	378.1	425.5	366.5	299.3	335.1	373.9	411.4	422.6	376.2
Cash & Cash Equivalents	39.2	10.4	15.9	33.9	33.4	10.5	41.9	30.9	32.1	39.3	8.2
Inventories	109.9	111.7	106.1	111.7	102.5	101.2	90.4	101.4	106.6	97.6	82.4
Trade Receivables	114.6	135.5	159.4	147.5	151.8	122.8	177.1	222.3	258.2	269.7	272.3
Non-current Assets	308.8	298.2	266.9	202.5	266.6	249.8	238.2	219.9	219.5	228.4	237.3
Property, Plant & Equipment	64.5	144.5	129.1	120.3	116.1	183.7	148.3	117.8	122.1	127.0	129.7
Intangible Assets	2.8	40.8	30.4	16.3	21.5	17.7	21.4	15.1	20.1	23.4	28.6
Total Liabilities	235.9	275.1	379.6	402.2	444.5	341.6	343.1	333.7	360.1	374.8	388.1
Current Liabilities	209.2	208.6	286.9	380.1	282.7	234.7	278.0	228.4	274.5	258.0	260.8
Non-current Liabilities	26.7	66.5	92.7	22.1	161.8	106.9	65.1	105.3	85.6	116.8	127.3
Total Equity	369.4	329.5	265.4	225.8	188.5	207.5	230.1	260.1	270.8	276.3	225.4
Share Capital	62.3	62.3	61.1	59.4	57.2	55.6	54.1	52.8	51.2	50.1	45.2
Retained Earnings	214.6	164.1	113.0	89.1	58.6	65.1	86.8	121.7	26.0	33.2	51.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	96.4	79.4	87.2	56.8	18.1	63.1	55.5	52.1	33.5	6.7	-4.2
Cash from Investing Activities	-7.2	14.1	-63.8	-18.9	-22.9	-79.4	-22.0	-13.9	-9.9	-8.8	-7.3
Purchase of Property, Plant & Equipment	11.8	8.3	27.3	9.9	7.5	12.4	9.2	7.7	7.3	8.1	5.6
Cash from Financing Activities	-59.8	-100.2	-41.2	-36.9	27.2	-14.0	-24.2	-41.2	-27.9	33.8	14.7
Dividends Paid	11.1	9.7	8.8	7.4	7.1	7.0	6.8	5.8	5.2	-2.7	-2.7
Net Change in Cash	29.4	-6.7	-17.9	0.9	22.5	-30.4	9.4	-3.0	-4.3	31.8	3.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	222.0	199.9	198.9	200.0	191.1	185.2	187.9	178.7	172.3	180.6
Cost of Revenue	116.7	101.4	109.1	105.4	100.4	101.1	104.9	92.3	101.2	97.6
Gross Profit	105.3	98.5	89.8	94.6	90.7	84.2	83.0	86.4	71.1	83.0
Selling, General & Administrative	71.9	64.9	74.4	62.6	65.7	62.2	64.9	59.8	59.5	56.8
Operating Income	33.3	33.6	15.5	32.0	25.0	22.0	18.1	26.5	11.6	26.2
Finance Income	1.4	2.2	3.5	1.3	1.8	1.9	3.8	1.2	2.4	3.1
Finance Costs	1.7	-1.8	2.6	1.6	1.8	2.8	4.2	2.1	3.9	4.5
Pretax Income	34.8	35.2	17.5	27.9	20.6	22.9	18.6	26.6	10.8	26.4
Income Tax Expense	6.9	7.7	2.2	-2.7	22.5	-5.4	2.1	6.7	2.3	6.4
Net Income	27.9	27.5	15.3	30.6	-1.9	17.5	16.6	19.8	8.5	20.1
Total Comprehensive Income	28.2	28.1	15.3	30.8	-3.0	17.4	26.1	20.3	8.2	19.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	659.9	621.6	605.3	611.6	590.1	611.0	604.6	636.9	663.9	657.4
Current Assets	344.5	308.9	296.5	332.0	324.8	323.5	306.4	361.0	392.7	389.2
Cash & Cash Equivalents	44.1	20.6	39.2	32.6	11.1	31.8	10.4	38.8	33.3	32.7
Inventories	111.7	114.7	109.9	116.3	119.5	121.6	111.7	116.4	110.6	111.8
Trade Receivables	117.8	115.2	114.6	124.4	125.3	126.3	135.5	137.1	160.3	154.8
Non-current Assets	315.4	312.7	308.8	279.6	265.3	287.5	298.2	275.8	271.2	268.3
Property, Plant & Equipment	139.1	138.9	64.5	139.0	139.9	142.4	144.5	125.1	127.4	127.7
Intangible Assets	68.1	66.6	2.8	55.4	47.2	44.3	40.8	38.4	31.2	28.2
Total Liabilities	250.0	239.8	235.9	257.5	266.8	280.0	275.1	333.1	380.4	382.2
Current Liabilities	220.6	211.4	209.2	220.1	230.5	219.2	208.6	254.8	292.7	295.5
Non-current Liabilities	29.3	28.5	26.7	37.4	36.3	60.8	66.5	78.3	87.7	86.7
Total Equity	409.9	381.8	369.4	354.1	323.3	331.1	329.5	303.8	283.5	275.3
Share Capital	62.3	62.3	62.3	62.3	62.3	62.3	62.3	62.3	62.3	62.3
Retained Earnings	254.2	226.3	214.6	199.2	168.7	170.5	164.1	151.8	132.0	123.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	42.5	17.5	27.6	46.9	-6.7	28.6	19.0	10.8	14.0	35.6
Cash from Investing Activities	-20.1	-35.4	-6.6	-3.0	-7.7	10.1	4.4	10.3	-1.9	1.3
Purchase of Property, Plant & Equipment	2.3	3.2	4.9	1.2	1.4	4.3	2.9	1.0	2.3	2.0
Cash from Financing Activities	1.3	-1.1	-14.2	-22.5	-5.8	-17.3	-52.7	-15.4	-11.7	-20.5
Dividends Paid	—	—	22.1	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	23.6	-19.0	6.8	21.4	-20.1	21.3	-29.3	5.8	0.4	16.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

001060 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	775.3	+7.8%	+4.2%	+7.2%	+6.0%
Operating income	94.5	+14.5%	+14.5%	—	+15.9%
Net income	61.5	-5.4%	+27.2%	—	+41.1%
EPS	₩2,642	-5.4%	+27.2%	—	+41.1%
Operating cash flow	96.4	+21.4%	+19.3%	+8.9%	—
Shareholders' equity	369.4	+12.1%	+17.8%	+12.2%	+5.1%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

001060 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	46.3%	45.0%	44.8%	42.1%	38.6%	32.4%
Operating margin	12.2%	11.5%	13.4%	9.2%	5.1%	-0.2%
Net margin	7.9%	9.0%	5.1%	4.4%	-0.2%	-2.8%
Return on equity	17.6%	21.9%	15.6%	14.4%	-0.7%	-7.0%
Return on assets	10.2%	10.4%	6.0%	4.7%	-0.2%	-2.7%
Operating cash flow / revenue	12.4%	11.0%	11.6%	8.3%	3.0%	11.5%
Capex / revenue	1.5%	1.2%	3.6%	1.4%	1.2%	2.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 001060

Symbol	Last Price
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
456160G2GBIO, Inc.	₩37,950 +5.7%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
358570GI Innovation, Inc.	₩8,090 +6.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.